Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Bridget Keenan
Description
Summary
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Bridget Keenan
Dr. Keenan completed her MD and PhD at the Johns Hopkins University School of Medicine, where she focused on using cancer vaccines to overcome immune suppression in the tumor microenvironment in mouse models of pancreatic cancer. She completed her Internal Medicine residency and Hematology/Oncology fellowship at UCSF.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Affini-T Therapeutics, Inc.
- ID
- NCT06105021
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 100 study participants
- Last Updated